UTHR vs. BBH

In the year-to-date period, UTHR achieves a -9.63% return, which is significantly lower than BBH's -5.50% return. Over the past 10 years, UTHR has outperformed BBH with an annualized return of 5.77%, while BBH has yielded a comparatively lower 1.49% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and VanEck Vectors Biotech ETF (BBH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current UTHR Sharpe Ratio is 0.57, which is higher than the BBH Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of UTHR and BBH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

UTHR has not paid dividends to shareholders, while BBH's dividend yield for the trailing twelve months is around 0.84%.

The maximum UTHR drawdown since its inception was -93.18%, which is greater than BBH's maximum drawdown of -72.69%. Use the drawdown chart below to compare losses from any high point for UTHR and BBH.

The current volatility for United Therapeutics Corporation (UTHR) is 8.09%, while VanEck Vectors Biotech ETF (BBH) has a volatility of 9.90%. This indicates that UTHR experiences smaller price fluctuations and is considered to be less risky than BBH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.